GLP3-RT: A Research Overview

Important regulatory note. GLP3-RT (Eli Lilly code LY3437943) is an investigational molecule in Phase 3 trials. As of mid-2026 it is not FDA approved, not EMA approved, and the only legal access pathway for human use is clinical-trial enrollment. This article is an educational summary of the published scientific literature for laboratory and research audiences only. It is not medical advice, a dosing guide, or a recommendation for human use. All VANTA products are sold strictly for in-vitro and laboratory research use only.

TL;DR: GLP3-RT (Eli Lilly code LY3437943) is an investigational once-weekly triple agonist that activates the GIP, GLP-1, and glucagon receptors — the first triple agonist to reach Phase 3. It is not FDA-approved as of mid-2026; the only legal human-use pathway is clinical-trial enrollment. It is the most-watched compound in metabolic research.

Last reviewed: July 2026.

What is GLP3-RT?

GLP3-RT is a synthetic peptide engineered as a triple agonist — it simultaneously activates three receptors: GIP, GLP-1, and glucagon. It is the first triple agonist of its kind to reach Phase 3 development. Where semaglutide engages one incretin receptor (GLP-1) and tirzepatide engages two (GIP/GLP-1), GLP3-RT adds a third (glucagon) — the defining feature that makes it a major subject of current metabolic research.

It is supplied as a lyophilized powder for laboratory reconstitution.

How does GLP3-RT work?

GLP3-RT works through its glucagon-receptor addition on top of the incretin effects it shares with GLP-1/GIP agonists. Beyond glucose-dependent insulin secretion, appetite signaling, and gastric emptying, glucagon-receptor engagement is studied for its effects on energy expenditure and hepatic lipid metabolism — which is why GLP3-RT has drawn specific research attention to liver-fat endpoints in addition to body-weight and glycemic measures.

What does the research on GLP3-RT establish?

GLP3-RT has an unusually strong evidence trajectory for a compound still in trials:

• Its Phase 2 data was published in the New England Journal of Medicine (2023).
• The Phase 3 TRIUMPH program has since reported pivotal results. TRIUMPH-4 (obesity + knee osteoarthritis, reported December 2025) and TRIUMPH-1 (topline reported May 21, 2026) delivered substantial weight reduction: in TRIUMPH-1, the 12 mg dose produced an average of 28.3% body-weight loss over 80 weeks, with 45.3% of participants losing ≥30% — a level long associated with bariatric surgery. These are single-arm-versus-placebo results, so cross-trial comparisons to tirzepatide are indicative rather than head-to-head.

(These are reported clinical-trial outcomes from Eli Lilly’s regulated program, stated here as scientific context, not as research-peptide claims.)

What this means for a research context — and an important caution

GLP3-RT is investigational and proprietary. There is no approved supply of any kind; the published data comes exclusively from Eli Lilly’s controlled trials. For a research audience this means two things: (1) the compound is a frontier reference point in incretin biology, and (2) any handling of research-grade material should be approached with full awareness of its investigational, patent-protected status. This is materially different from a long-public research peptide.

How does GLP3-RT compare to tirzepatide and semaglutide?

GLP3-RT represents the current frontier of the incretin spectrum: GLP-1 mono-agonist (semaglutide) → GIP/GLP-1 dual agonist (tirzepatide) → GIP/GLP-1/glucagon triple agonist (GLP3-RT). It is the most-watched compound in metabolic research as of 2026.

What is the regulatory status of GLP3-RT in 2026?

As of mid-2026, GLP3-RT is not FDA-approved, not EMA-approved, and available for human use only through clinical-trial enrollment. Following the positive TRIUMPH-1 topline results announced May 21, 2026, Eli Lilly has indicated a New Drug Application (NDA) filing is anticipated before the end of 2026, with potential approval commonly projected for 2027–2028 pending review and remaining trial readouts (TRIUMPH-2, TRIUMPH-3). It remains an investigational, patent-protected molecule with no approved supply of any kind; the published efficacy data comes exclusively from Lilly’s controlled trials. Research-grade material is a strictly research-use-only context — consult qualified legal counsel regarding its investigational, proprietary status.

Laboratory handling

• Storage (lyophilized): cold, protected from light; long-term at −20 °C.
• After reconstitution: refrigerated (2–8 °C), used within the lab’s protocol window.
• Verification: confirm identity/purity against the batch COA (HPLC, mass spec).

VANTA supplies research-grade material with a batch-specific COA. See our Certificates of Analysis page.

Frequently asked (research) questions

Is GLP3-RT approved? No. It is investigational, in Phase 3 trials, with no approved prescription pathway as of 2026; Eli Lilly has signaled an NDA filing anticipated by year-end 2026.

How does it differ from tirzepatide? Tirzepatide is a dual GIP/GLP-1 agonist; GLP3-RT adds a third receptor target (glucagon), making it a triple agonist.

---

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist GLP3-RT for obesity — a Phase 2 trial. N Engl J Med. 2023;389:514–526. doi:10.1056/NEJMoa2301972.
2. Eli Lilly and Company. TRIUMPH-4 topline results (press release, Dec 2025); TRIUMPH-1 topline results (press release, May 21, 2026).
3. Rosenstock J, et al. GLP3-RT Phase 2 in type 2 diabetes. Lancet. 2023.

Verify each source independently. This summary is research context only and does not describe or recommend human use. GLP3-RT is an investigational, patent-protected molecule; consult qualified legal counsel regarding research-grade supply.